Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Park, Jin-Woo | - |
dc.contributor.author | Kim, Kyoung-Ah | - |
dc.contributor.author | Park, Ji-Young | - |
dc.date.accessioned | 2021-08-31T11:02:04Z | - |
dc.date.available | 2021-08-31T11:02:04Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2020-02 | - |
dc.identifier.issn | 0269-3879 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/57767 | - |
dc.description.abstract | Teneligliptin is a recently developed dipeptidyl peptidase-4 (DPP-4) inhibitor for the treatment of type 2 diabetes mellitus. To study simultaneous pharmacokinetics of teneligliptin and its major active metabolite, teneligliptin sulfoxide in human plasma, we developed and validated a LC-MS/MS method. The analytes were detected in the positive mode using multiple reaction monitoring (teneligliptin: m/z 427.2 -> 243.1; teneligliptin-d(8): m/z 435.2 -> 251.3; teneligliptin sulfoxide: m/z 443.2 -> 68.2). The method demonstrated accuracy, precision, and linearity over the concentration range of 5 to 1000 ng/mL for teneligliptin and 2.5 to 500 ng/mL for teneligliptin sulfoxide. The developed method is the first fully validated method capable of simultaneous determination of teneligliptin and its active metabolite, teneligliptin sulfoxide in plasma. The suitability of the method was successfully demonstrated in terms of quantification of teneligliptin and teneligliptin sulfoxide pharmacokinetics in plasma samples collected from healthy volunteers. The measurement of plasma metabolite/parent ratio of teneligliptin was feasible by this method. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | WILEY | - |
dc.subject | INHIBITOR TENELIGLIPTIN | - |
dc.subject | PHARMACOKINETICS | - |
dc.title | Development of a liquid chromatography/tandem-mass spectrometry assay for the simultaneous determination of teneligliptin and its active metabolite teneligliptin sulfoxide in human plasma | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Park, Ji-Young | - |
dc.identifier.doi | 10.1002/bmc.4721 | - |
dc.identifier.scopusid | 2-s2.0-85077151539 | - |
dc.identifier.wosid | 000504462500001 | - |
dc.identifier.bibliographicCitation | BIOMEDICAL CHROMATOGRAPHY, v.34, no.2 | - |
dc.relation.isPartOf | BIOMEDICAL CHROMATOGRAPHY | - |
dc.citation.title | BIOMEDICAL CHROMATOGRAPHY | - |
dc.citation.volume | 34 | - |
dc.citation.number | 2 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Analytical | - |
dc.relation.journalWebOfScienceCategory | Pharmacology & Pharmacy | - |
dc.subject.keywordPlus | INHIBITOR TENELIGLIPTIN | - |
dc.subject.keywordPlus | PHARMACOKINETICS | - |
dc.subject.keywordAuthor | teneligliptin | - |
dc.subject.keywordAuthor | teneligliptin sulfoxide | - |
dc.subject.keywordAuthor | LC-MS | - |
dc.subject.keywordAuthor | MS | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.